Expanding Your Transfemoral TAVI Access Options with IVL
Published: 28 April 2021
In this session, Prof Nicolas Van Mieghem and Dr Joost Daemen (Erasmus Medical Center, Rotterdam, NL) combine presentation, case review, and discussion to provide expert insight into TAVI access options with IVL. This programme addresses the challenges associated with problematic calcium, examines the role of IVL in cracking calcium in situ, and highlights the importance of its mechanism of action in minimising complications.
- Learn how IVL can break down the barriers of calcification to enable transfemoral (TF) access
- Understand how IVL’s safe and efficacious mechanism of action (MOA) reduces complications
- View our patient case and understand how IVL seamlessly fits into the procedural steps simplifying complex calcified transfemoral access
- Interact with our panelists in a live Q&A format following
- Interventional Cardiologists
- General Cardiologists
More from this programme
Nicolas M Van Mieghem
From an early age, Professor Nicolas Maria Van Mieghem decided to pursue a career that would help others. “I enjoy the feeling of being able to help someone or do something important for them. I wanted to enter a profession that would channel my energy— I was always a busy child,” he says.
A budding athlete, he was a member of Belgium’s national swimming team but soon realized that medicine was his true calling. His father was a general cardiologist and one of his biggest influences early in his career.
Professor Van Mieghem initially intended to train as a cardiac surgeon but decided to specialise in interventional cardiology instead, following advice from a mentor. This decision was cemented when he read the first-in-human case report of transcatheter aortic valve implantation (TAVI) in Circulation by Alain Cribier in 2002.
His mantra is mens sana in corpore sano (a…
Dr Joost Daemen, MD, PhD obtained his degree in medicine at the Erasmus University Medical Center, Rotterdam in 2005 and did 2 years of internal medicine training and 4 years of general cardiology training at the Thoraxcenter, Rotterdam.
Joost is actively involved in several drug-eluting stent trials and is Principal Investigator of 4 trials focusing on the safety and efficacy of renal sympathetic denervation in hypertension, heart failure, vasospastic angina and heart failure. Joost is a member of the editorial board of EuroIntervention and the Netherlands Heart Journal, member of Young ICIN, and has completed courses in biomedical statistics and device training.